A long-term follow-up study on hepatitis B surface antigen–positive patients undergoing allogeneic hematopoietic stem cell transplantation
2005
The long-term hepatic complications after allogeneic
hematopoietic stem celltransplantation (HSCT) in hepatitis B virus (HBV) endemic area are unknown. We examined the
serologicaland liver-related outcome of 803 consecutive patients who received allogeneic HSCTs, with a median follow-up period of 83 months (range, 0.5-155 months). Late HBV-related hepatitis occurred in 2 of the 721 hepatitis B surface antigen–negative (
HBsAg–) recipients compared with 16 of the 82
HBsAg+ recipients after HSCT (0.3% vs 19.5%; P < .001 by log-rank). Liver cirrhosis developed in 8 of the 82
HBsAg+ recipients compared with none of the 721
HBsAg– recipients (9.8% vs 0%; P < .001 by log-rank). Twenty of the 31 (64.5%)
HBsAg+ recipients of
hematopoietic stem cellsfrom donors with natural immunity to HBV had sustained
serologicclearance of
HBsAgafter HSCT. Eight of the 62 recipients without sustained
HBsAgclearance compared with none of the 20 recipients with sustained
HBsAgclearance developed liver cirrhosis (12.9% vs 0%; P = .02 by log-rank). Our study showed that long-term hepatic complications occur in a significant proportion of
HBsAg+ patients after HSCT and the incidence of liver cirrhosis is reduced in those with sustained
serologicclearance of
HBsAgafter HSCT.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
45
References
67
Citations
NaN
KQI